Search

C29H30N6O6, monoclinic, P21/c (no. 14), a = 12.3134(3) Å, b = 21.2095(4) Å, c = 10.8503(2) Å, β = 100.549(1)°, V = 2785.8 Å3, Z = 4, Rgt(F) = 0.0422, wRref(F2) = 0.1205, T = 200 K

C16H16N2, triclinic, P1̅ (no. 2), a = 6.2920(1) Å, b = 8.2151(2) Å, c = 12.4139(2) Å, α = 88.547(1)°, β = 81.649(1)°, γ = 89.546(1)°, V = 634.7 Å3, Z = 2, Rgt(F) = 0.0398, wRref(F2) = 0.1101, T = 200 K.

C17H29ClN2O2, monoclinic, P21 (no. 4), a = 9.5140(5) Å, b = 7.2916(4) Å, c = 13.0720(8) Å, β = 97.658(2)°, V = 898.8 Å3, Z = 2, Rgt(F) = 0.0343, wRref(F2) = 0.0957, T = 200 K.

C4H7NO3, monoclinic, P21/c (no. 14), a = 4.8110(2) Å, b = 11.5030(5) Å, c = 9.7660(4) Å, β = 97.864(2)°, V = 535.4 Å3, Z = 4, Rgt(F) = 0.0356, wRref(F2) = 0.1099, T = 200 K.

C16H13ClN2O, monoclinic, P21/c (no. 14), a = 7.9510(2) Å, b = 13.2274(3) Å, c = 12.8923(3) Å, β = 90.172(1)°, V = 1355.9 Å3, Z = 4, Rgt(F) = 0.0314, wRref(F2) = 0.0834, T = 200 K.

C14H10BrN, orthorhombic, Fdd2 (no. 43), a = 24.196(1) Å, b = 47.123(2) Å, c = 4.0402(2) Å, V = 4606.5 Å3, Z = 16, Rgt(F) = 0.0275, wRref(F2) = 0.0671, T = 200 K.

C16H15BrO2, monoclinic, P21/c (no. 14), a = 4.8925(2) Å, b = 9.6531(3) Å, c = 29.896(1) Å, β = 97.802(2)°, V = 1398.9 Å3, Z = 4, Rgt(F) = 0.0445, wRref(F2) = 0.0894, T = 200 K

The article discusses the crystal structure of desvenlafaxinium 3,5-dinitrobenzoate 3,5-dinitrobenzoic acid monohydrate, C30H35N5O15. Topics discussed include the source of material, experimental data, and the study on the compound which is considered as the first non-hormonal based treatment for menopause. Also provided is a table which shows information on data collection.

The article discusses the crystal structure of desvenlafaxinium 3,5-dinitrobenzoate 3,5-dinitrobenzoic acid monohydrate, C30H35N5O15. Topics discussed include the source of material, experimental data, and the study on the compound which is considered as the first non-hormonal based treatment for menopause. Also provided is a table which shows information on data collection.